| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/10/2004 | WO2004022128A3 Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols |
| 09/10/2004 | WO2004007444A3 N-hydroxyamide derivatives possessing antibacterial activity |
| 09/10/2004 | WO2003087092A3 Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
| 09/10/2004 | WO2003079984A3 Substituted tetracycline compounds |
| 09/10/2004 | WO2003070897A3 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 09/10/2004 | WO2003003979A3 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 09/10/2004 | WO2002097053A3 Small molecule antagonists of bcl2 family proteins |
| 09/10/2004 | CA2517575A1 Growth promotion method |
| 09/10/2004 | CA2517074A1 Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| 09/10/2004 | CA2517052A1 Polyvalent immunogen |
| 09/10/2004 | CA2516579A1 Method of detecting onset risk of encephalitis or encephalopathy |
| 09/10/2004 | CA2516465A1 Chemical process for the preparation of intermediates to obtain n-formyl hydroxylamine compounds |
| 09/09/2004 | US20040177388 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 09/09/2004 | US20040176610 Indolone oxazolidinones and derivatives thereof |
| 09/09/2004 | US20040176609 Compounds used as bactericides for treatment of infections |
| 09/09/2004 | US20040176587 Process for the preparation of l-ribavirin |
| 09/09/2004 | US20040176570 Intermediates and enzymes of the non-mevalonate isoprenoid pathway |
| 09/09/2004 | US20040176473 Methods for delivering compounds into a cell |
| 09/09/2004 | US20040176458 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 09/09/2004 | US20040176439 coadministration of agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F) |
| 09/09/2004 | US20040176431 Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use |
| 09/09/2004 | US20040176428 treatment of Type 2 diabetes mellitus, obesity and lipid disorders; coadministration with HMG CoA reductase inhibitors |
| 09/09/2004 | US20040176422 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 09/09/2004 | US20040176414 principle metabolite of cisapride; has both 5-HT3 antagonistic and 5-HT4 agonistic; devoid of central nervous system effects; separating racemic mixture by liquid chromatography over a chiral stationary phase |
| 09/09/2004 | US20040176411 especially useful for treating asthma and/or rhinitis; example compound N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide |
| 09/09/2004 | US20040176400 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 09/09/2004 | US20040176394 Administering heterocyclic esters such as 5-(2,4-Dimethyl-phenyl)-3-(8-hydroxy-quinolin-2-ylamino)-5-methyl-dihydro-furan-2-one for prophylaxis of headaches, sepsis, neurodegenerative diseases, or as analgesics, antiischemic or antidiabetic agents |
| 09/09/2004 | US20040176382 treatment of inflammation, proliferative diseases, and certain cardiovascular disorders as well as Alzheimer's disease; |
| 09/09/2004 | US20040176379 agonist effect from one or more of a somatostatin subtype receptor; diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X; inhibiting the proliferation of helicobacter pylori |
| 09/09/2004 | US20040176374 Arylsulfonamides as antiviral agents |
| 09/09/2004 | US20040176367 1-Amino 1H-imidazoquinolines |
| 09/09/2004 | US20040176365 1,8-Naphthyridin-2(1H)-one derivatives; antiasthmatic, antihistamine, and bronchodilator agents; nontoxic, side effect reduction |
| 09/09/2004 | US20040176362 Matrix metalloproteinase inhibitors, treatment of tumor necrosis factor mediated diseases; autoimmune and neurodegenerative disorders; anticarcinogenic and antiinflammatory agents |
| 09/09/2004 | US20040176350 Carbapenem compound |
| 09/09/2004 | US20040176349 Antibacterial composition |
| 09/09/2004 | US20040176337 Benzoquinolizine-2-carboxylic acid-containing compositions |
| 09/09/2004 | US20040176334 7-and 9- carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 09/09/2004 | US20040176326 N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof |
| 09/09/2004 | US20040176323 Pharmaceutical composition comprising lysophophatidic acid |
| 09/09/2004 | US20040176320 Use of at least one glycoinhibitor substance |
| 09/09/2004 | US20040176319 Cellular uptake of bioactive agents |
| 09/09/2004 | US20040176309 Siglec inhibitors |
| 09/09/2004 | US20040176297 Characterizing and predicting responses; identifying most efficient, cost effective and/or convenient treatment regimens; computer profiling |
| 09/09/2004 | US20040176279 Flint glycoforms |
| 09/09/2004 | US20040176252 Well tolerated; intracellularly increasing cAMP; antiasthmatics, antiinflammatories: regulation of eosinophiles activation and degranulation |
| 09/09/2004 | US20040175803 Interferon-alpha induced gene |
| 09/09/2004 | US20040175703 to be administered by inhalation, infusion, injection, or orally relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference in vitro and in vivo; genetic engineering |
| 09/09/2004 | US20040175437 preventing and treating certain inflammatory diseases, degenerative diseases and viral diseases in mammals |
| 09/09/2004 | US20040175419 controlling crystallization parameters of active ingredient to achieve increased compactability; compacting the active ingredient into a tablet |
| 09/09/2004 | US20040175418 Teste masking pharmaceutical composition |
| 09/09/2004 | US20040175395 Contains connecting disulfide bridge; humanized monoclonal and polyclonal antibodies; diagnostic kits for respiratory syncytial virus |
| 09/09/2004 | US20040175393 Cloning and recombinant production of polistinae venom enzymes, such as phospholipase and hyaluronidase, and imunological therapies based thereon |
| 09/09/2004 | US20040175378 Monoclonal antibody 3G4, or an antigen-binding region or immunoconjugate thereof, produced by hybridoma ATCC PTA 4545; binds to phosphatidyl serine |
| 09/09/2004 | US20040175365 Administering primer and boosting composition comprising source of one or more CD8+ T cell epitopes of melanoma from a source of non-replicating or replication-deficient recombinant poxvirus vector in the human |
| 09/09/2004 | US20040175353 Cyanoacrylate compositions for prophylactic or therapeutic treatment of diseases manifesting themselves in and/or damage cutaneous tissue |
| 09/09/2004 | DE10107663B4 Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung Testosterone-containing transdermal therapeutic system, process for its preparation and its use |
| 09/08/2004 | EP1454905A1 Novel substance fki-1083 and process for producing the same |
| 09/08/2004 | EP1454897A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY |
| 09/08/2004 | EP1454624A1 Antiviral, antibacterial pharmaceutical composition of cantharidic anhydride and method of preparation thereof |
| 09/08/2004 | EP1454137A2 Use of a labeled ligand having human cd4 specificity for producing a diagnostic used in the analysis of migration and/or distribution patterns of cell populations |
| 09/08/2004 | EP1454136A2 Methods and means for influencing intracellular communication and intracellular organelle transport |
| 09/08/2004 | EP1453965A2 Dna vaccine |
| 09/08/2004 | EP1453962A2 Inhibitor oligonucleotides and their use for specific repression of a gene |
| 09/08/2004 | EP1453913A2 Novel substituted alkane compounds and uses thereof |
| 09/08/2004 | EP1453909A1 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 09/08/2004 | EP1453862A2 Novel immunoadhesins for treating and preventing toxicity and pathogen-mediated diseases |
| 09/08/2004 | EP1453855A1 Antimicrobial bolisin peptides |
| 09/08/2004 | EP1453853A2 Mixture of peptides originating from a nef protein and applications thereof |
| 09/08/2004 | EP1453847A1 6-o-acyl ketolide derivatives of erythromycine useful as antibacterials |
| 09/08/2004 | EP1453846A1 Macrolides |
| 09/08/2004 | EP1453845A2 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 09/08/2004 | EP1453844A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 09/08/2004 | EP1453841A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them |
| 09/08/2004 | EP1453840A1 Phosphonates useful as modulators of t-gamma-9-delta-2 lymphocyte activity |
| 09/08/2004 | EP1453837A2 Targeted therapeutics and uses thereof |
| 09/08/2004 | EP1453834A1 Anhydrous crystal form of valaciclovir hydrochloride |
| 09/08/2004 | EP1453832A1 Ring fused pyrazole derivatives |
| 09/08/2004 | EP1453830A1 Pyrazolo-pyridine derivatives as antiherpes agents |
| 09/08/2004 | EP1453829A1 Sulfonamido substituted imidazopyridines |
| 09/08/2004 | EP1453824A1 New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| 09/08/2004 | EP1453820A1 Substituted 6h-dibenzo c,h]chromenes as estrogenic agents |
| 09/08/2004 | EP1453782A2 Substituted phenyl naphthalenes as estrogenic agents |
| 09/08/2004 | EP1453777A1 Functionalized higher diamondoids |
| 09/08/2004 | EP1453768A1 Antimicrobial alkali-silicate glass ceramic and the use thereof |
| 09/08/2004 | EP1453548A2 Compositions for and methods of treating and preventing sirs/sepsis |
| 09/08/2004 | EP1453547A2 Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
| 09/08/2004 | EP1453538A2 Method of purifying hepatitis a virus particles and vaccine preparation |
| 09/08/2004 | EP1453537A1 Composition for viral preservation |
| 09/08/2004 | EP1453536A1 Composition for the preservation of viruses |
| 09/08/2004 | EP1453534A1 A process for the preparation of a non-toxic anthrax vaccine |
| 09/08/2004 | EP1453529A2 Treatment of sepsis with tafi |
| 09/08/2004 | EP1453507A2 Solubilized topoisomerase poison agents |
| 09/08/2004 | EP1453504A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation |
| 09/08/2004 | EP1453482A1 Radioopaque sustained release pharmaceutical system |
| 09/08/2004 | EP1453481A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 09/08/2004 | EP1453471A2 Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| 09/08/2004 | EP1345603A4 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 09/08/2004 | EP1292313B1 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 09/08/2004 | EP1194416B1 Halopyrimidines |
| 09/08/2004 | EP1176971B1 Use of phyllanthus for treating chronic inflammatory and fibrotic processes |